Agenus Announced Five Presentations Featuring Botensilimab (Bot, An Fc-enhanced Anti-CTLA-4 Antibody) Plus Balstilimab (Bal, An Anti-PD-1 Antibody) At The Upcoming American Society Of Clinical Oncology Gastrointestinal Cancers Symposium

BenzingaDec 18 20:35

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

BusinesswireDec 18 20:30

H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating

Futu NewsDec 6 01:35 · Ratings

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

BenzingaDec 6 00:12

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

BusinesswireDec 5 20:30

H.C. Wainwright Maintains Agenus(AGEN.US) With Hold Rating, Maintains Target Price $7

Futu NewsNov 28 01:31 · Ratings